GB201705263D0 - Novel inhibitors - Google Patents

Novel inhibitors

Info

Publication number
GB201705263D0
GB201705263D0 GBGB1705263.0A GB201705263A GB201705263D0 GB 201705263 D0 GB201705263 D0 GB 201705263D0 GB 201705263 A GB201705263 A GB 201705263A GB 201705263 D0 GB201705263 D0 GB 201705263D0
Authority
GB
United Kingdom
Prior art keywords
novel inhibitors
inhibitors
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1705263.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivoryon Therapeutics AG
Original Assignee
Probiodrug AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug AG filed Critical Probiodrug AG
Priority to GBGB1705263.0A priority Critical patent/GB201705263D0/en
Publication of GB201705263D0 publication Critical patent/GB201705263D0/en
Priority to JP2019553478A priority patent/JP7674811B2/ja
Priority to US16/497,040 priority patent/US11339152B2/en
Priority to PCT/EP2018/058391 priority patent/WO2018178384A1/en
Priority to IL269196A priority patent/IL269196B2/en
Priority to MX2019011544A priority patent/MX2019011544A/es
Priority to NZ792694A priority patent/NZ792694A/en
Priority to CN201880035826.8A priority patent/CN110719910B/zh
Priority to CA3057783A priority patent/CA3057783A1/en
Priority to AU2018246382A priority patent/AU2018246382C1/en
Priority to BR112019019553-0A priority patent/BR112019019553A2/pt
Priority to EP18718725.7A priority patent/EP3601269A1/en
Priority to KR1020247039667A priority patent/KR20250002689A/ko
Priority to IL307911A priority patent/IL307911A/en
Priority to NZ757601A priority patent/NZ757601A/en
Priority to CN202310828597.8A priority patent/CN117024352A/zh
Priority to EA201992120A priority patent/EA201992120A1/ru
Priority to CA3221839A priority patent/CA3221839A1/en
Priority to IL297534A priority patent/IL297534A/en
Priority to KR1020197028930A priority patent/KR102737532B1/ko
Priority to ZA2019/05811A priority patent/ZA201905811B/en
Priority to MX2022007317A priority patent/MX2022007317A/es
Priority to US17/737,602 priority patent/US12384772B2/en
Priority to JP2022082769A priority patent/JP7589191B2/ja
Priority to AU2022246405A priority patent/AU2022246405B2/en
Priority to JP2024107135A priority patent/JP2024153639A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB1705263.0A 2017-03-31 2017-03-31 Novel inhibitors Ceased GB201705263D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1705263.0A GB201705263D0 (en) 2017-03-31 2017-03-31 Novel inhibitors
KR1020197028930A KR102737532B1 (ko) 2017-03-31 2018-04-03 신규한 억제제
KR1020247039667A KR20250002689A (ko) 2017-03-31 2018-04-03 신규한 억제제
NZ757601A NZ757601A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors
PCT/EP2018/058391 WO2018178384A1 (en) 2017-03-31 2018-04-03 Novel inhibitors
IL269196A IL269196B2 (en) 2017-03-31 2018-04-03 Heterocyclic glutaminyl cyclase inhibitors, uses therof as medicaments and pharmaceutical compositions comprising same
MX2019011544A MX2019011544A (es) 2017-03-31 2018-04-03 Inhibidores novedosos.
NZ792694A NZ792694A (en) 2017-03-31 2018-04-03 Novel glutaminyl cyclase inhibitors
CN201880035826.8A CN110719910B (zh) 2017-03-31 2018-04-03 新的抑制剂
CA3057783A CA3057783A1 (en) 2017-03-31 2018-04-03 Novel inhibitors of glutaminyl cyclase
AU2018246382A AU2018246382C1 (en) 2017-03-31 2018-04-03 Novel inhibitors
BR112019019553-0A BR112019019553A2 (pt) 2017-03-31 2018-04-03 inibidores
EP18718725.7A EP3601269A1 (en) 2017-03-31 2018-04-03 Novel inhibitors
JP2019553478A JP7674811B2 (ja) 2017-03-31 2018-04-03 新規の阻害剤
IL307911A IL307911A (en) 2017-03-31 2018-04-03 New inhibitors
US16/497,040 US11339152B2 (en) 2017-03-31 2018-04-03 Inhibitors
CN202310828597.8A CN117024352A (zh) 2017-03-31 2018-04-03 新的抑制剂
EA201992120A EA201992120A1 (ru) 2017-03-31 2018-04-03 Новые ингибиторы
CA3221839A CA3221839A1 (en) 2017-03-31 2018-04-03 Novel inhibitors of glutaminyl cyclase
IL297534A IL297534A (en) 2017-03-31 2018-04-03 New inhibitors
ZA2019/05811A ZA201905811B (en) 2017-03-31 2019-09-03 Novel inhibitors
MX2022007317A MX2022007317A (es) 2017-03-31 2019-09-26 Inhibidores novedosos.
US17/737,602 US12384772B2 (en) 2017-03-31 2022-05-05 Inhibitors
JP2022082769A JP7589191B2 (ja) 2017-03-31 2022-05-20 新規の阻害剤
AU2022246405A AU2022246405B2 (en) 2017-03-31 2022-10-05 Novel inhibitors
JP2024107135A JP2024153639A (ja) 2017-03-31 2024-07-03 新規の阻害剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1705263.0A GB201705263D0 (en) 2017-03-31 2017-03-31 Novel inhibitors

Publications (1)

Publication Number Publication Date
GB201705263D0 true GB201705263D0 (en) 2017-05-17

Family

ID=58682483

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1705263.0A Ceased GB201705263D0 (en) 2017-03-31 2017-03-31 Novel inhibitors

Country Status (15)

Country Link
US (2) US11339152B2 (enExample)
EP (1) EP3601269A1 (enExample)
JP (3) JP7674811B2 (enExample)
KR (2) KR20250002689A (enExample)
CN (2) CN117024352A (enExample)
AU (2) AU2018246382C1 (enExample)
BR (1) BR112019019553A2 (enExample)
CA (2) CA3221839A1 (enExample)
EA (1) EA201992120A1 (enExample)
GB (1) GB201705263D0 (enExample)
IL (3) IL297534A (enExample)
MX (2) MX2019011544A (enExample)
NZ (2) NZ792694A (enExample)
WO (1) WO2018178384A1 (enExample)
ZA (1) ZA201905811B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
WO2019211741A1 (en) 2018-05-02 2019-11-07 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
SG11202102674RA (en) * 2018-10-05 2021-04-29 Pfizer Boron containing pde4 inhibitors
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
EP3906226A4 (en) * 2019-01-06 2023-03-15 Psomagen, Inc. HTRA INHIBITORS AND CAGA INHIBITORS AND THEIR USE
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
KR102433502B1 (ko) * 2020-01-17 2022-08-18 재단법인 대구경북첨단의료산업진흥재단 신규 화합물, 이의 제조방법 및 이의 용도
US20230142654A1 (en) * 2020-01-17 2023-05-11 Daegu-Gyeongbuk Medical Innovation Foundation Novel compound, preparation method thereof, and use thereof
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4259617B1 (en) * 2020-12-10 2024-10-23 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
EP4388734A4 (en) 2021-08-18 2025-05-07 Augmedics Ltd. Stereoscopic display and digital magnifier for close-up augmented reality viewing
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用
WO2023205173A1 (en) * 2022-04-20 2023-10-26 Blacksmith Medicines, Inc. Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
CN114560817B (zh) * 2022-04-25 2022-10-25 北京大学第三医院（北京大学第三临床医学院） 一种用于抑制纤维化的小分子药物及其应用
AR130003A1 (es) 2022-08-03 2024-10-23 Boehringer Ingelheim Int Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention
CN120379972A (zh) * 2022-12-20 2025-07-25 深圳湾实验室 一种靶向usp1的小分子抑制剂及其应用
AU2023411110A1 (en) 2022-12-22 2025-04-24 Boehringer Ingelheim International Gmbh Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
IL322702A (en) 2023-03-13 2025-10-01 Boehringer Ingelheim Int History of phenylpiperidine as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase-like protein
TW202521532A (zh) 2023-08-04 2025-06-01 德商百靈佳殷格翰國際股份有限公司 作為麩醯胺醯基肽環轉移酶及麩醯胺醯基肽環轉移酶樣蛋白之抑制劑的哌啶基吡啶基甲腈衍生物
US20250059165A1 (en) 2023-08-04 2025-02-20 Boehringer Ingelheim International Gmbh Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
WO2025036713A1 (en) 2023-08-14 2025-02-20 Boehringer Ingelheim International Gmbh Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163647T1 (de) * 1993-08-26 1998-03-15 Ono Pharmaceutical Co 4-aminopyrimidin derivate
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US20090048301A1 (en) * 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US7449465B2 (en) * 2003-07-16 2008-11-11 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
NZ548197A (en) * 2004-01-12 2010-06-25 Serono Lab Thiazole derivatives and use thereof
CN1960731B (zh) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
DE602005024274D1 (de) * 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JP5320291B2 (ja) 2006-07-14 2013-10-23 ケモセントリックス， インコーポレイテッド トリアゾリルピリジルベンゼンスルホンアミド類
US20100216767A1 (en) * 2006-12-22 2010-08-26 Mina Aikawa Quinazolines for pdk1 inhibition
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
WO2009032861A1 (en) * 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
CA2734486A1 (en) * 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010026212A1 (en) * 2008-09-04 2010-03-11 Probiodrug Ag Novel inhibitors
CA2772488C (en) * 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
NZ602312A (en) * 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) * 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CA2815330A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
BR112013011600B1 (pt) * 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
JP6218808B2 (ja) * 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
CN104955824B (zh) * 2012-11-20 2017-09-22 豪夫迈·罗氏有限公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
NZ712352A (en) * 2013-03-15 2016-07-29 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
MA40957A (fr) * 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
WO2016180536A1 (en) * 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives
CA2994917A1 (en) 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US10221191B2 (en) * 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Also Published As

Publication number Publication date
US20220274977A1 (en) 2022-09-01
AU2018246382B2 (en) 2022-06-16
US12384772B2 (en) 2025-08-12
CN110719910B (zh) 2023-07-21
US20200377493A1 (en) 2020-12-03
JP7674811B2 (ja) 2025-05-12
IL297534A (en) 2022-12-01
KR20250002689A (ko) 2025-01-07
CN110719910A (zh) 2020-01-21
JP2024153639A (ja) 2024-10-29
CA3057783A1 (en) 2018-10-04
IL307911A (en) 2023-12-01
AU2018246382C1 (en) 2024-07-04
AU2018246382A1 (en) 2019-10-17
WO2018178384A1 (en) 2018-10-04
IL269196A (en) 2019-11-28
NZ792694A (en) 2025-10-31
US11339152B2 (en) 2022-05-24
MX2019011544A (es) 2019-12-16
JP7589191B2 (ja) 2024-11-25
NZ757601A (en) 2023-02-24
JP2020512373A (ja) 2020-04-23
IL269196B2 (en) 2024-04-01
CA3221839A1 (en) 2018-10-04
EP3601269A1 (en) 2020-02-05
AU2022246405A1 (en) 2022-10-27
AU2022246405B2 (en) 2024-08-01
JP2022110130A (ja) 2022-07-28
KR20190136005A (ko) 2019-12-09
EA201992120A1 (ru) 2020-01-29
ZA201905811B (en) 2020-06-24
BR112019019553A2 (pt) 2020-04-22
MX2022007317A (es) 2022-07-13
CN117024352A (zh) 2023-11-10
IL269196B1 (en) 2023-12-01
KR102737532B1 (ko) 2024-12-04

Similar Documents

Publication Publication Date Title
ZA201905811B (en) Novel inhibitors
SG11202106520VA (en) Kif18a inhibitors
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
IL260217B (en) lsd1 driven
IL258158A (en) New profortin inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201705971D0 (en) Inhibitor compounds
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201501004D0 (en) Inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL276013A (en) pi4kiiibeta inhibitors
EP3067422C0 (en) CT-1 INHIBITORS
GB201520949D0 (en) Inhibitors
GB201721465D0 (en) Inhibitors
HK40102998A (zh) 新的抑制剂
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201720145D0 (en) Inhibitor compounds
GB201715589D0 (en) Protease inhibitors
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)